MEDICAL UPDATE: ACTG Study of Combination Antivirals

MEDICAL UPDATE: ACTG Study of Combination Antivirals

Being Alive; April 1992
presented by Mark Katz MD and reported by Jim Stoecker

The AIDS Clinical Trial Group (ACTG) has announced protocol 175 which will study the effectiveness of combination antivirals. This study is being conducted at centers throughout the US. Participants need to have CD4 counts in the 200-500 range. All who take part in the study will receive some form of antiviral therapy.

ACTG 175 will compare four regimens: AZT alone, ddI alone, AZT and ddI together, and AZT and ddC in combination. This may very well be a landmark study, but, due to the size of the study, it may be some time before we have any results to report. For more information about participating in ACTG 175, you can call the national number, 800.TRIALS-A, or locally, 310.206.6414 (UCLA), 310.212.5291 (UCLA Harbor) or 213.343.8280 (USC).
920401
BA920405

AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1992 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1992. AEGIS.